WGS Quote, Financials, Valuation and Earnings

Quest Diagnostics, Inc. has a net margin of -6.54% compared to GeneDx Holdings Corp.'s net margin of 9.13%. GeneDx Holdings Corp.'s return on equity of 0.82% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.

GeneDx Holdings Corp. has a consensus price target of $170.89, signalling upside risk potential of 26.23%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $198.06 which suggests that it could grow by 13.54%. Given that GeneDx Holdings Corp. has higher upside potential than Quest Diagnostics, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Quest Diagnostics, Inc..

GeneDx Holdings Corp. has a beta of 2.053, which suggesting that the stock is 105.339% more volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.788%.

GeneDx Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.81% to investors and pays a quarterly dividend of $0.80 per share. GeneDx Holdings Corp. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GeneDx Holdings Corp. quarterly revenues are $116.7M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. GeneDx Holdings Corp.'s net income of -$7.6M is lower than Quest Diagnostics, Inc.'s net income of $257M. Notably, GeneDx Holdings Corp.'s price-to-earnings ratio is 2,245.11x while Quest Diagnostics, Inc.'s PE ratio is 20.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings Corp. is 9.65x versus 1.82x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Guardant Health, Inc. has a net margin of -6.54% compared to GeneDx Holdings Corp.'s net margin of -34.97%. GeneDx Holdings Corp.'s return on equity of 0.82% beat Guardant Health, Inc.'s return on equity of -8518.58%.

GeneDx Holdings Corp. has a consensus price target of $170.89, signalling upside risk potential of 26.23%. On the other hand Guardant Health, Inc. has an analysts' consensus of $119.09 which suggests that it could grow by 8.1%. Given that GeneDx Holdings Corp. has higher upside potential than Guardant Health, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Guardant Health, Inc..

GeneDx Holdings Corp. has a beta of 2.053, which suggesting that the stock is 105.339% more volatile than S&P 500. In comparison Guardant Health, Inc. has a beta of 1.584, suggesting its more volatile than the S&P 500 by 58.44%.

GeneDx Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings Corp. pays -- of its earnings as a dividend. Guardant Health, Inc. pays out -- of its earnings as a dividend.

GeneDx Holdings Corp. quarterly revenues are $116.7M, which are smaller than Guardant Health, Inc. quarterly revenues of $265.2M. GeneDx Holdings Corp.'s net income of -$7.6M is higher than Guardant Health, Inc.'s net income of -$92.7M. Notably, GeneDx Holdings Corp.'s price-to-earnings ratio is 2,245.11x while Guardant Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings Corp. is 9.65x versus 15.15x for Guardant Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of -6.54% compared to GeneDx Holdings Corp.'s net margin of 13.85%. GeneDx Holdings Corp.'s return on equity of 0.82% beat Illumina, Inc.'s return on equity of 30.55%.

GeneDx Holdings Corp. has a consensus price target of $170.89, signalling upside risk potential of 26.23%. On the other hand Illumina, Inc. has an analysts' consensus of $131.56 which suggests that it could fall by -6.75%. Given that GeneDx Holdings Corp. has higher upside potential than Illumina, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Illumina, Inc..

GeneDx Holdings Corp. has a beta of 2.053, which suggesting that the stock is 105.339% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.409, suggesting its more volatile than the S&P 500 by 40.855%.

GeneDx Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GeneDx Holdings Corp. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

GeneDx Holdings Corp. quarterly revenues are $116.7M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. GeneDx Holdings Corp.'s net income of -$7.6M is lower than Illumina, Inc.'s net income of $150M. Notably, GeneDx Holdings Corp.'s price-to-earnings ratio is 2,245.11x while Illumina, Inc.'s PE ratio is 31.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings Corp. is 9.65x versus 5.19x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings, Inc. has a net margin of -6.54% compared to GeneDx Holdings Corp.'s net margin of 7.34%. GeneDx Holdings Corp.'s return on equity of 0.82% beat Labcorp Holdings, Inc.'s return on equity of 10.25%.

GeneDx Holdings Corp. has a consensus price target of $170.89, signalling upside risk potential of 26.23%. On the other hand Labcorp Holdings, Inc. has an analysts' consensus of $299.71 which suggests that it could grow by 19.02%. Given that GeneDx Holdings Corp. has higher upside potential than Labcorp Holdings, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Labcorp Holdings, Inc..

GeneDx Holdings Corp. has a beta of 2.053, which suggesting that the stock is 105.339% more volatile than S&P 500. In comparison Labcorp Holdings, Inc. has a beta of 0.999, suggesting its less volatile than the S&P 500 by 0.053000000000003%.

GeneDx Holdings Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Labcorp Holdings, Inc. offers a yield of 1.14% to investors and pays a quarterly dividend of $0.72 per share. GeneDx Holdings Corp. pays -- of its earnings as a dividend. Labcorp Holdings, Inc. pays out 32.58% of its earnings as a dividend. Labcorp Holdings, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GeneDx Holdings Corp. quarterly revenues are $116.7M, which are smaller than Labcorp Holdings, Inc. quarterly revenues of $3.6B. GeneDx Holdings Corp.'s net income of -$7.6M is lower than Labcorp Holdings, Inc.'s net income of $261.5M. Notably, GeneDx Holdings Corp.'s price-to-earnings ratio is 2,245.11x while Labcorp Holdings, Inc.'s PE ratio is 24.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GeneDx Holdings Corp. is 9.65x versus 1.54x for Labcorp Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.